CS
SNDX icon

Credit Suisse’s Syndax Pharmaceuticals SNDX Stock Holding History

Credit Suisse’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.05M Buy
86,223
+13,448
+18% +$300K ﹤0.01% 1841
2023
Q4 		$1.57M Buy
72,775
+1,635
+2% +$25.1K ﹤0.01% 2038
2023
Q3 		$1.03M Sell
71,140
-11,248
-14% -$213K ﹤0.01% 2282
2023
Q2 		$1.72M Buy
82,388
+26,689
+48% +$556K ﹤0.01% 2017
2023
Q1 		$1.18M Buy
55,699
+1,057
+2% +$26.3K ﹤0.01% 2231
2022
Q4 		$1.39M Buy
54,642
+9,443
+21% +$220K ﹤0.01% 2113
2022
Q3 		$1.09M Buy
45,199
+12,467
+38% +$280K ﹤0.01% 2274
2022
Q2 		$630K Buy
32,732
+3,093
+10% +$51.5K ﹤0.01% 2696
2022
Q1 		$516K Sell
29,639
-965
-3% -$16.2K ﹤0.01% 2953
2021
Q4 		$670K Buy
30,604
+3,993
+15% +$73.8K ﹤0.01% 3624
2021
Q3 		$508K Buy
26,611
+2,666
+11% +$44.4K ﹤0.01% 3786
2021
Q2 		$411K Sell
23,945
-1,948
-8% -$35.7K ﹤0.01% 3947
2021
Q1 		$578K Sell
25,893
-29,623
-53% -$669K ﹤0.01% 3677
2020
Q4 		$1.24M Sell
55,516
-6,059
-10% -$126K ﹤0.01% 3179
2020
Q3 		$908K Buy
61,575
+9,641
+19% +$147K ﹤0.01% 3007
2020
Q2 		$770K Buy
+51,934
New +$791K ﹤0.01% 3063

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse's SNDX Position: Q1 2024 in Review

Credit Suisse increased its Syndax Pharmaceuticals (SNDX) stake by 18% in Q1 2024, buying an estimated $300K and bringing the position to 86,223 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Credit Suisse first reported a position in SNDX in Q2 2020 and has held it in 16 quarters since. 189 funds tracked by Wall St. Rank hold SNDX as of Q1 2024.

  • Credit Suisse held 86,223 shares of Syndax Pharmaceuticals worth $2.05M as of Q1 2024.
  • Credit Suisse bought 13,448 Syndax Pharmaceuticals shares in Q1 2024, an estimated $300K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1841 holding.
  • Credit Suisse first reported a position in Syndax Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
  • 189 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.